Edition:
United States

DiaMedica Therapeutics Inc (DMA.V)

DMA.V on TSX Venture Exchange

0.39CAD
1:51pm EDT
Change (% chg)

$0.03 (+8.33%)
Prev Close
$0.36
Open
$0.38
Day's High
$0.39
Day's Low
$0.38
Volume
24,500
Avg. Vol
57,405
52-wk High
$0.42
52-wk Low
$0.14

Latest Key Developments (Source: Significant Developments)

Diamedica announces the initiation of phase 2 trial evaluating DM199 (Recombinant Human KLK1) in patients with acute ischemic stroke
Monday, 11 Sep 2017 08:00am EDT 

Sept 11 (Reuters) - Diamedica Therapeutics Inc :Diamedica announces the initiation of phase 2 trial evaluating DM199 (recombinant human Klk1) in patients with acute ischemic stroke.  Full Article

DiaMedica presents updated positive dm199 phase 1b trial identifying a superior subcutaneous delivery profile
Monday, 13 Mar 2017 08:00am EDT 

DiaMedica Therapeutics Inc - : DiaMedica presents updated positive dm199 phase 1b trial identifying a superior subcutaneous delivery profile .DiaMedica Therapeutics Inc says no treatment-limiting adverse events were reported in any dose group.  Full Article

Diamedica announces positive top-line results from DM199 bridging clinical trial
Tuesday, 20 Dec 2016 08:00am EST 

Diamedica Inc : Diamedica announces positive top-line results from DM199 bridging clinical trial . Diamedica Inc says plans to use results of DM199 bridging clinical trial study to guide phase II dosing in upcoming clinical trials .Diamedica Inc says no treatment limiting adverse events were reported in any dose group in the trial.  Full Article

Hermed Capital to invest $4 mln for total of 20 mln shares of Diamedica
Monday, 18 Jul 2016 12:38am EDT 

Diamedica Inc : Intends to use offering proceeds toward advancing its research and development programs including an upcoming dm199 clinical trial, general corporate purposes . Diamedica announces strategic investment by hermed capital healthcare fund .Agreement provides for hermed capital to invest $4 million for a total of 20 million shares of co at $0.20/common share in two tranches.  Full Article

DiaMedica Inc Increases Size of Non-Brokered Private Placement
Tuesday, 24 Nov 2015 11:59am EST 

DiaMedica Inc:it has increased the size of the previously announced non- brokered private placement from up to 3,000,000 Units to up to 4,500,000 Units in the capital of the Company at an issue of $0.10 per Unit for gross proceeds of up to $450,000.proceeds will be used by the Company to support development with DM199 for the treatment of vascular diseases and for other working capital purposes.Offering is scheduled to close around November 25th, subject to regulatory approvals.  Full Article

BRIEF-Diamedica announces the initiation of phase 2 trial evaluating DM199 (Recombinant Human KLK1) in patients with acute ischemic stroke

* Diamedica announces the initiation of phase 2 trial evaluating DM199 (recombinant human Klk1) in patients with acute ischemic stroke Source text for Eikon: Further company coverage: